κ Agonists as a novel therapy for menopausal hot flashes
Amy E Oakley1, Robert A Steiner, Charles Chavkin
11Department of Physiology and Biophysics, University of Washington, Seattle, WA 2Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 3Department of Pharmacology, University of Washington, Seattle, WA.
Menopause (New York, N.Y.)
|May 20, 2015
Summary
This pilot study found that kappa (κ) agonists may reduce the frequency of menopausal hot flashes. Further research is needed to confirm these findings for women experiencing vasomotor symptoms.
Area of Science:
- Neuroendocrinology
- Reproductive Medicine
- Pharmacology
Background:
- Postmenopausal hot flashes have an unclear etiology, hindering effective therapy development.
- Hypothalamic KNDy neurons, sensitive to estrogen, regulate GnRH and LH secretion.
- Dynorphin's potential inhibitory role via kappa opioid receptors is implicated in hot flash mechanisms.
Purpose of the Study:
- To investigate the hypothesis that manipulating KNDy neurons can reduce hot flashes.
- To evaluate the efficacy of a kappa (κ) agonist in mitigating menopausal vasomotor symptoms.
Main Methods:
- A double-blind, cross-over, placebo-controlled pilot study.
- Twelve postmenopausal women with moderate to severe hot flashes participated.
- Interventions included placebo, standard-dose, and low-dose pentazocine/naloxone (a κ agonist).
- Hot flash frequency, severity, and LH pulsatility were monitored.
Main Results:
- Kappa (κ) agonist treatment significantly reduced hot flash frequency compared to placebo (P=0.025).
- No significant difference in hot flash intensity was observed between groups.
- Luteinizing hormone (LH) pulsatility showed varied correlation with objective hot flashes.
Conclusions:
- Kappa (κ) agonists show potential in managing menopausal vasomotor symptoms.
- This pilot study provides preliminary evidence for the role of κ agonists in hot flash reduction.
More Related Videos
Related Concept Videos
01:28Menopause
5.2K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.2K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
778
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
778
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.1K
01:25Analgesia and Pain Management
3.1K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.1K
01:22Hormonal Regulation of the Menstrual Cycle
2.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K